A Phase II, Nonrandomized Open Trial Assessing Pain Efficacy with Radium-223 in Symptomatic Metastatic Castration-resistant Prostate Cancer
Year: 2021
Type: article
Study design: Clinical Trial
Source: Clinical Genitourinary Cancer
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
Funders: Boehringer Ingelheim, Amgen, Bristol-Myers Squibb, Astellas Pharma US, AstraZeneca, Merck, Patient-Centered Outcomes Research Institute, American Society of Clinical Oncology, AbbVie, Karyopharm Therapeutics, Bayer Corporation, American Medical Association, Taiho Pharmaceutical, Exelixis, Clovis Oncology, Bayer Fund, INOVIO Pharmaceuticals, Constellation Pharmaceuticals, Mirati Therapeutics, Genentech, Centers for Medicare and Medicaid Services, National Cancer Institute
OpenAlex ID: W3152584866